PriceTargets.com logo

NYSE:NUVB - Nuvation Bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.40
  • Forecasted Upside: 73.48 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$10.03 As of 04/16/2021 01:00 AM ET
▲ +0.04 (0.40%)
1 month | 3 months | 12 months
Get New Nuvation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.40
▲ +73.48% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $17.40, with a high forecast of $20.00 and a low forecast of $15.00. The average price target represents a 73.48% upside from the last price of $10.03.
Buy
The current consensus among 6 polled investment analysts is to buy stock in Nuvation Bio.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021Royal Bank of CanadaInitiated CoverageOutperform$15.00N/A
i
Rating by Kennen MacKay at Royal Bank of Canada
4/6/2021Royal Bank of CanadaInitiated CoverageOutperform$15.00High
i
3/15/2021BTIG ResearchReiterated RatingBuy$16.00High
i
3/15/2021WedbushInitiated CoverageOutperform$20.00High
i
Rating by D. Nierengarten at Wedbush
3/15/2021BMO Capital MarketsInitiated CoverageOutperform$16.00High
i
3/15/2021Jefferies Financial GroupInitiated CoverageBuy$20.00High
i
3/15/2021CowenInitiated CoverageOutperformHigh
i
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$20.00High
i
3/8/2021CowenInitiated CoverageOutperformHigh
i
3/8/2021WedbushInitiated CoverageOutperform$20.00High
i
Rating by D. Nierengarten at Wedbush
3/8/2021BTIG ResearchInitiated CoverageBuy$16.00High
i
3/8/2021BMO Capital MarketsInitiated CoverageOutperform$16.00High
i
(Data available from 4/18/2016 forward)
Nuvation Bio logo
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Read More

Today's Range

Now: $10.03
$10.00
$10.04

50 Day Range

MA: $11.43
$9.83
$14.57

52 Week Range

Now: $10.03
$8.56
$15.07

Volume

25,807 shs

Average Volume

813,002 shs

Market Capitalization

$2.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvation Bio?

The following Wall Street research analysts have issued stock ratings on Nuvation Bio in the last twelve months: BMO Capital Markets, BTIG Research, Cowen Inc, Jefferies Financial Group Inc., Royal Bank of Canada, and Wedbush.
View the latest analyst ratings for NUVB.

What is the current price target for Nuvation Bio?

5 Wall Street analysts have set twelve-month price targets for Nuvation Bio in the last year. Their average twelve-month price target is $17.40, suggesting a possible upside of 73.5%. Jefferies Financial Group Inc. has the highest price target set, predicting NUVB will reach $20.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $15.00 for Nuvation Bio in the next year.
View the latest price targets for NUVB.

What is the current consensus analyst rating for Nuvation Bio?

Nuvation Bio currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NUVB will outperform the market and that investors should add to their positions of Nuvation Bio.
View the latest ratings for NUVB.

What other companies compete with Nuvation Bio?

Other companies that are similar to Nuvation Bio include AbCellera Biologics, Sana Biotechnology, Abcam, Cronos Group, Genus, Abcam, BTG, Seer, MorphoSys, ImmunityBio, Immunocore, BioAtla, Cullinan Oncology, Silverback Therapeutics and Kinnate Biopharma.

How do I contact Nuvation Bio's investor relations team?

The company's listed phone number is 650-245-3818. The official website for Nuvation Bio is www.nuvationbio.com.